Global manufacturing supply chains are changing and having an overextended supply chain means extra external costs. Being able to react to the needs of the market and having production close to the primary market are becoming the norm. In recent years, multinational pharmaceutical companies have one by one opted for strategic outsourcing in the face of mounting financial pressure. Most small and medium pharmaceutical companies across the globe have elected to choose contract manufacturing as well.
Regarding the current state of biopharmaceutical CDMOs and CMOs, Taiwan Healthcare+ took the time to talk to EirGenix, last year's winner of Asia's Best Contract Manufacturing Organization Award, about the various kinds of support and services CDMOs can provide their clients. During the interview, Dr. Lee-Cheng Liu, President & CEO of EirGenix, Inc., noted that a high barrier to entry exists for biopharmaceutical CDMOs. The number of CDMOs with quality production capability is limited, and most of them are small in scale. EirGenix holds a competitive edge in multiple areas such as geographic location, expert personnel, infrastructure and cost structure. For the year 2018, EiGenix is seeking to actively expand its CDMO business in Asia.
Dr. Chih-Jung Chang, EirGenix's Vice President of the CDMO Unit, emphasized that EirGenix has the ability and production capacity to satisfy the client's needs, from the development of clinical drugs to commercial production. Its new manufacturing plant exclusively adopts the single-use bioreactor process and has met international standards in production efficiency and manufacturing quality while achieving cost-effectiveness. EirGenix is confident that it can become one of the top strategic outsourcing partners for pharmaceutical companies in neighboring Japan and China, as well as for multinational pharmaceutical companies in Asia.
At the upcoming 2018 Taiwan Healthcare Expo, EirGenix will have a comprehensive showcase of its production capabilities including past projects, core technology platform, production facility, and services - a complete and exhaustive demonstration of its expert contract manufacturing ability for its clients in Asia.
|Date of Establishment||August. 1973|
|Paid-In Capital||1,033 million|
|Market Capitalization||3,315 million|
|Production Factory (Inspections)||Xizhi, Taipei (Japan PMDA, Taiwan FDA)
Source: Company, Research Center for Biotechnology and Medicine Policy.